Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma

The existence of tumor heterogeneity is widely recognized; however, heterogeneity of the antitumor response in multiple tumor nodules in the same patient has not been reported. Sintilimab, a monoclonal antiprogrammed cell death receptor-1 (PD-1) antibody, was used to treat patients with unresectable...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Yingying, Wen, Liang, Chen, Wen, Zhao, Jianhui, Yang, Yixiao, Wei, Tao, Zhang, Jian, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372450/
https://www.ncbi.nlm.nih.gov/pubmed/35965575
http://dx.doi.org/10.3389/fonc.2022.899811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372450/
https://www.ncbi.nlm.nih.gov/pubmed/35965575
http://dx.doi.org/10.3389/fonc.2022.899811

Ejemplares similares